专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013067483A8 DELIVERY SYSTEMS FOR IMPROVING ORAL BIOAVAILABILITY OF FENOBAM, ITS HYDRATES, AND SALTS 审中-公开
标题翻译：用于改善FENOBAM，其水合物和盐的口服生物利用度的递送系统
公开(公告)号：WO2013067483A8
公开(公告)日：2014-04-17
申请号：PCT/US2012063528
申请日：2012-11-05
申请人： MURTY SANTOS B , MURTY RAM B
发明人： MURTY SANTOS B , MURTY RAM B
IPC分类号： A61K31/4166 , A61K31/17 , A61K47/00 , A61K47/34 , A61K47/48 , A61P25/24
CPC分类号： A61K9/0002 , A61K9/0065 , A61K9/1075 , A61K9/205 , A61K9/2846 , A61K9/4866 , A61K31/4168
摘要： A delivery system for administration to a patient of Fenobam, its hydrates, and salts optimizes solubility and dissolution properties of Fenobam, its hydrates, and salts using either microemulsions, solid dispersions, cyclodextrin, gastroretentives, enteric coatings, and sustained delivery techniques to provide a vehicle for oral administration of these drugs.
摘要翻译：用于给予Fenobam患者，其水合物和盐的递送系统优化Fenobam，其水合物和使用微乳液，固体分散体，环糊精，胃肠炎，肠溶衣和持续递送技术的溶解度和溶解性质，以提供用于口服这些药物的载体。

2. 发明申请

WO2012033478A1 AN IMPROVED ORAL DOSAGE FORM OF TETRAHYDROCANNABINOL AND A METHOD OF AVOIDING AND/OR SUPPRESSING HEPATIC FIRST PASS METABOLISM VIA TARGETED CHYLOMICRON/LIPOPROTEIN DELIVERY 审中-公开
标题翻译：改进的四氢萘啶醇的口服剂型和通过靶向的CHYLOMICRON / LIPOPROTEIN递送避免和/或抑制HEPAN首次通过代谢的方法
公开(公告)号：WO2012033478A1
公开(公告)日：2012-03-15
申请号：PCT/US2010/047952
申请日：2010-09-07
申请人： MURTY PHARMACEUTICALS, INC. , MURTY, Ram, B. , MURTY, Santos, B.
发明人： MURTY, Ram, B. , MURTY, Santos, B.
IPC分类号： A61K31/35 , A61K31/232 , A61K31/20 , A61K47/30 , A61K9/107
CPC分类号： A61K31/352 , A61K9/1075 , A61K31/473 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/44
摘要： Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron/lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic/non-amphiphilic solutes to induce semi-solid formation for targeted release rates.
摘要翻译：提供自乳化药物递送系统以改善药物化合物的抗坏血酸或其他大麻素的溶解度，稳定性和生物利用度。将药物化合物溶解在油性介质（例如甘油三酯和/或含有培养基和/或长链饱和，单不饱和和/或多不饱和游离脂肪酸的混合甘油酯和/或游离脂肪酸）中与至少一种表面活性剂。表面活性剂促进自乳化，从而促进靶向的乳糜微粒/脂蛋白递送和通过哺乳动物肠道的最佳生物利用度。剂型可以任选地包括共溶剂，抗氧化剂，粘度调节剂，细胞色素P450代谢抑制剂，P-GP外排抑制剂和两亲/非两亲性溶质以诱导靶向释放速率的半固体形成。

3. 发明申请

WO2007056242A1 IMPROVED DELIVERY OF TETRAHYDROCANNABINOL 审中-公开
标题翻译：改善四氯氰菊酯的输送
公开(公告)号：WO2007056242A1
公开(公告)日：2007-05-18
申请号：PCT/US2006/043126
申请日：2006-11-03
申请人： MURTY PHARMACEUTICALS, INC. , MURTY, Ram, B. , MURTY, Santos, B.
发明人： MURTY, Ram, B. , MURTY, Santos, B.
IPC分类号： A01N43/16
CPC分类号： A61K9/107 , A61K9/4858 , A61K31/352 , A61K31/353 , A61K31/655 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/34 , A61K47/44
摘要： A self-emulsifying drug delivery system to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron delivery and optimal bioavailability to a mammalian intestinal lumen. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic/non-amphiphilic solutes to induce semi-solid formation for targeted release rates.
摘要翻译：一种自乳化药物输送系统，用于改善药物化合物的抗坏血酸或其他大麻素的溶出度，稳定性和生物利用度。将药物化合物溶解在油性介质（例如甘油三酯和/或含有培养基和/或长链饱和，单不饱和和/或多不饱和游离脂肪酸的混合甘油酯和/或游离脂肪酸）中与至少一种表面活性剂。表面活性剂促进自乳化，从而促进靶向的乳糜微粒递送和对哺乳动物肠腔的最佳生物利用度。剂型可以任选地包括共溶剂，抗氧化剂，粘度调节剂，细胞色素P450代谢抑制剂，P-GP外排抑制剂和两亲/非两亲性溶质以诱导靶向释放速率的半固体形成。

4. 发明申请

WO2013067483A1 DELIVERY SYSTEMS FOR IMPROVING ORAL BIOAVAILABILITY OF FENOBAM, ITS HYDRATES, AND SALTS 审中-公开
标题翻译：用于改善FENOBAM，其水合物和盐的口服生物利用度的递送系统
公开(公告)号：WO2013067483A1
公开(公告)日：2013-05-10
申请号：PCT/US2012/063528
申请日：2012-11-05
申请人： MURTY, Santos B. , MURTY, Ram, B.
发明人： MURTY, Santos B. , MURTY, Ram, B.
IPC分类号： A61K31/4166 , A61K31/17 , A61K47/34 , A61K47/48 , A61K47/00 , A61P25/24
CPC分类号： A61K9/0002 , A61K9/0065 , A61K9/1075 , A61K9/205 , A61K9/2846 , A61K9/4866 , A61K31/4168
摘要： A delivery system for administration to a patient of Fenobam, its hydrates, and salts optimizes solubility and dissolution properties of Fenobam, its hydrates, and salts using either microemulsions, solid dispersions, cyclodextrin, gastroretentives, enteric coatings, and sustained delivery techniques to provide a vehicle for oral administration of these drugs.
摘要翻译：用于给予Fenobam患者，其水合物和盐的递送系统优化Fenobam，其水合物和使用微乳液，固体分散体，环糊精，胃肠炎，肠溶衣和持续递送技术的溶解度和溶解性质，以提供用于口服这些药物的载体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式